ERK1/2 phosphorylation has already been proposed as a molecular target in myelodysplastic syndromes, where the MEK inhibitors U0126 and PD98059 successfully re-sensitized Bortezomib-resistant cells to the drug [101]. Here, MAPK3 is linked to myelodysplastic syndrome.